Weilan Zuo Johnson, MD | |
700 San Gabriel Village Blvd Ste 105, Georgetown, TX 78626-5594 | |
(512) 819-9910 | |
(512) 819-9970 |
Full Name | Weilan Zuo Johnson |
---|---|
Gender | Female |
Speciality | Dermatology |
Experience | 13 Years |
Location | 700 San Gabriel Village Blvd Ste 105, Georgetown, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1992091326 | NPI | - | NPPES |
8124NN | Other | TX | BCBS PV# |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | P8919 (Texas) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Oliver Street 5.01(a) Inc | 0042464125 | 141 |
News Archive
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today its results for the three months ended March 31, 2011.
Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.
Discontinuing the anemia drug epoetin may be more effective than reducing the dose for normalizing potentially dangerous high hemoglobin levels in hemodialysis patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results provide useful information about the balance required between administering epoetin and achieving target hemoglobin levels.
Newest results were showcased at the International Myology School in Moscow on 16th - 19th May 2018. KFU was represented by Junior Research Associate Mikhail Mavlikeev.
› Verified 2 days ago
Entity Name | Oliver Street 5.01(a) Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1457695413 PECOS PAC ID: 0042464125 Enrollment ID: O20130128000189 |
News Archive
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today its results for the three months ended March 31, 2011.
Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.
Discontinuing the anemia drug epoetin may be more effective than reducing the dose for normalizing potentially dangerous high hemoglobin levels in hemodialysis patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results provide useful information about the balance required between administering epoetin and achieving target hemoglobin levels.
Newest results were showcased at the International Myology School in Moscow on 16th - 19th May 2018. KFU was represented by Junior Research Associate Mikhail Mavlikeev.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Weilan Zuo Johnson, MD 700 San Gabriel Village Blvd Ste 105, Georgetown, TX 78626-5594 Ph: (512) 819-9910 | Weilan Zuo Johnson, MD 700 San Gabriel Village Blvd Ste 105, Georgetown, TX 78626-5594 Ph: (512) 819-9910 |
News Archive
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today its results for the three months ended March 31, 2011.
Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.
Discontinuing the anemia drug epoetin may be more effective than reducing the dose for normalizing potentially dangerous high hemoglobin levels in hemodialysis patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results provide useful information about the balance required between administering epoetin and achieving target hemoglobin levels.
Newest results were showcased at the International Myology School in Moscow on 16th - 19th May 2018. KFU was represented by Junior Research Associate Mikhail Mavlikeev.
› Verified 2 days ago
Christopher Jones Jr., M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3010 Williams Dr, Suite 177, Georgetown, TX 78628 Phone: 512-930-3909 Fax: 512-240-5469 | |
Dr. Mary A Evers, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1900 Scenic Dr Ste 2208, Georgetown, TX 78626 Phone: 512-868-9800 Fax: 512-868-9811 | |
Eric A Adelman, D.O. Dermatology Medicare: Medicare Enrolled Practice Location: 4513 Williams Dr, Georgetown, TX 78633 Phone: 512-930-3909 Fax: 512-869-5868 | |
Elizabeth Cabrera, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4513 Williams Dr, Georgetown, TX 78633 Phone: 512-930-3909 Fax: 512-869-5868 | |
Dr. Eugen Stancut, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1900 Scenic Dr Ste 2208, Georgetown, TX 78626 Phone: 512-868-9800 Fax: 512-868-9811 | |
Rachelle Lou Naridze, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 700 San Gabriel Village Blvd Ste 105, Georgetown, TX 78626 Phone: 512-598-8757 | |
Dr. Mollie Melinda Jan, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3010 Williams Dr Ste 210, Georgetown, TX 78628 Phone: 512-756-2525 Fax: 512-756-2533 |